Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of$ 0.44. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -56.82%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of$ 0.47 per share when it actually produced a loss of $0.48, delivering a surprise of -2.13%.Over the last four quart ...